cyclin dependent kinase inhibitor 2A
Last updated 20 Mar 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The CDKN2A gene provides instructions for making several proteins. The most well-studied are the p16(INK4A) and the p14(ARF) proteins. Both function as tumour suppressors, which means they keep cells from growing and dividing too rapidly or in an uncontrolled way. Both proteins are also involved in stopping cell division in older cells (senescence).
Video picks for GenesVideo library
Normal function
The CDKN2A gene provides instructions for making several proteins. The most well-studied are the p16(INK4A) and the p14(ARF) proteins. Both function as tumour suppressors, which means they keep cells from growing and dividing too rapidly or in an uncontrolled way. Both proteins are also involved in stopping cell division in older cells (senescence).
The p16(INK4A) protein attaches (binds) to two other proteins called CDK4 and CDK6. These proteins help regulate the cell cycle, which is the cell's way of replicating itself in an organized, step-by-step fashion. CDK4 and CDK6 normally stimulate the cell to continue through the cycle and divide. However, binding of p16(INK4A) blocks CDK4's or CDK6's ability to stimulate cell cycle progression. In this way, p16(INK4A) controls cell division. Cells begin to produce p16(INK4A) when they are no longer able to undergo cell division.
The p14(ARF) protein protects a different protein called p53 from being broken down. The p53 protein is an important tumour suppressor that is essential for regulating cell division, senescence, and self-destruction (apoptosis). By protecting p53, p14(ARF) also helps prevent tumour formation. The p14(ARF) and p53 proteins are often made in cells that are unable to undergo cell division.
Conditions referring to this gene or chromosome
Other names
ARF
CDK4 inhibitor p16-INK4
CDK4I
CDKN2
cell cycle negative regulator beta
CMM2
cyclin-dependent kinase 4 inhibitor A
cyclin-dependent kinase inhibitor 2A
cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
cyclin-dependent kinase inhibitor 2A isoform p12
cyclin-dependent kinase inhibitor 2A isoform p14ARF
cyclin-dependent kinase inhibitor 2A isoform p16gamma
cyclin-dependent kinase inhibitor 2A isoform p16INK4a
INK4
INK4A
MLM
MTS-1
MTS1
multiple tumour suppressor 1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
Patient picks for Genes

Treatment and medication
ACE inhibitors
ACE inhibitors are medicines that are used mainly in the treatment of high blood pressure (hypertension) and heart failure. They are also used in some people with diabetes, for some forms of kidney disease, and after a heart attack, to help protect the heart. They have a variety of effects on the body. Their ability to relax blood vessels is one of the most important. The side-effects most commonly associated with ACE inhibitors are usually minor. A common side-effect is a persistent dry cough.
by Dr Toni Hazell, FRCGP

Treatment and medication
Proton pump inhibitors
Proton pump inhibitors reduce the amount of acid made by the stomach. They are commonly used to treat acid reflux and ulcers of the stomach and part of the gut called the duodenum. Most people who take a proton pump inhibitor do not develop any side-effects.
by Dr Philippa Vincent, MRCGP

Medicine
Trandolapril - an ACE inhibitor
Take trandolapril once daily. The first dose may make you feel dizzy, so it is best taken at bedtime. Some painkillers and indigestion remedies interfere with trandolapril. Ask your pharmacist for advice before you buy any medicines 'over the counter'. Some people taking trandolapril can develop a troublesome cough. If this happens to you, let your doctor know.
by Michael Stewart, MRPharmS

Medicine
Captopril - an ACE inhibitor
Captopril is used to treat a number of different conditions. The first dose may make you feel dizzy, so it is best taken just before you go to bed. Some painkillers and indigestion remedies interfere with captopril, so ask your pharmacist for advice before you buy any medicines. Some people taking captopril develop a troublesome cough. If this happens to you, let your doctor know.
by Michael Stewart, MRPharmS

Medicine
Fosinopril - an ACE inhibitor
The first dose of fosinopril can make you feel dizzy. It is best taken at bedtime. Fosinopril is generally well tolerated but if you develop a troublesome cough, you should let your doctor know. Some painkillers and indigestion remedies interfere with fosinopril. Ask your pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS

Medicine
Perindopril - an ACE inhibitor
Perindopril is given to treat a number of different conditions. It is generally well tolerated, although some people can develop a troublesome cough. If this happens to you, let your doctor know. The first dose of perindopril can make you feel dizzy, so it is best taken at bedtime. Some painkillers and indigestion remedies interfere with perindopril, so ask your pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS
Related patient information and medicines

Patient information leaflet
Pompholyx
Pompholyx is a type of eczema where there are itchy blisters on the hands and feet, followed by inflamed and dry skin. The condition is usually long-term, with symptoms that come and go at various times. In some cases it has been shown to be helpful for the treatment of pompholyx. Janus Kinase (JAK) inhibitors : these medications, available as.

Patient information leaflet
Mouth cancer
Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Patient information leaflet
Chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. What is... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Mastocytosis and mast cell disorders
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (such as interferon), bone marrow transplant or... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Patient information leaflet
Mitral regurgitation
The mitral valve is a heart valve that lies between the left atrium and left ventricle. ...eart - mitral valve incompetence i88_l.jpg What is mitral regurgitationAlthough medicines cannot correct mitral regurgitation, some medicines may be prescribed to help ease symptoms, or to help prevent complications by managing your blood pressure - for.

Patient information leaflet
Myelofibrosis
The gene mutation that occurs in most people affected by myelofibrosis is a mutation in Janus Kinase 2 (JAK2). A group of medicines called JAK inhibitors (JAKi) may be given to some people with myelofibrosis to treat severe anaemia or an enlarged spleen. Dr Sarah Jarvis, December 2021 NICE guidance on drug treatments for myelofibrosis Fedratinib.
Further reading and references
- cyclin dependent kinase inhibitor 2A; MedlinePlus, National Library of Medicine.
- Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness RA, Jeganathan KB, Verzosa GC, Pezeshki A, Khazaie K, Miller JD, van Deursen JM. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016 Feb 11;530(7589):184-9. doi: 10.1038/nature16932. Epub 2016 Feb 3.
- Canepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life. 2007 Jul;59(7):419-26. doi: 10.1080/15216540701488358.
- Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006 Oct 15;66(20):9818-28. doi: 10.1158/0008-5472.CAN-06-0494.
- He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017 Jun 1;169(6):1000-1011. doi: 10.1016/j.cell.2017.05.015.
- Jeck WR, Siebold AP, Sharpless NE. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell. 2012 Oct;11(5):727-31. doi: 10.1111/j.1474-9726.2012.00871.x. Epub 2012 Aug 30.
- Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, Solomon B. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer. 2014 Aug 15;135(4):887-95. doi: 10.1002/ijc.28727. Epub 2014 Jan 30.
- Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 2013 Mar;35(3):454-63. doi: 10.1002/hed.23100. Epub 2012 Aug 21.
- Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol. 2014 Oct;25(10):1889-1900. doi: 10.1093/annonc/mdu143. Epub 2014 Apr 8.
- Potrony M, Puig-Butille JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol. 2014 Nov;71(5):888-95. doi: 10.1016/j.jaad.2014.06.036. Epub 2014 Jul 24.
- Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
- Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Hoiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Peric B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

